The influence of switching from risperidone to paliperidone on the extrapyramidal symptoms and cognitive function in elderly patients with schizophrenia: A preliminary open-label trial

References

• Arakawa R, Ito H, Takano A, Takahashi H, Morimoto T, Sassa T, et al. 2008. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology (Ber1) 197:229–235.
   PubMed Web of Science ®Google Scholar
• Bernes TR. 1989. A rating scale for drug induced akathisia. Br J Psychiatry 154:672–676.
   Google Scholar
• Boom S, Thyssen A, Crauwels H, Molz KH, Cleton A, Janssens L, et al. 2009. The influence of hepatic impairment on the pharmacokinetics of paliperidone. Int J Clin Pharmacol Ther 47:606–616.
   PubMed Web of Science ®Google Scholar
• Cuesta MJ, Peralta V, Zarzuela A. 2001. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: A longitudinal study. Schizophr Res 48:17–28.
   PubMed Web of Science ®Google Scholar
• Fang J, Bourin M, Baker GB. 1999. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol 359:147–151.
   PubMed Web of Science ®Google Scholar
• Furukori H, Niioka T, Yasui-Furukori N. 2010. Pharmacokinetics of paliperidone. Jpn J Clin Psychopharmacol 13:2039–2044 (in Japanese).
   Google Scholar
• Gray JA, Roth BL. 2007. The pipeline and future of drug development in schizophrenia. Mol Psychiatry 12:904–922.
   PubMed Web of Science ®Google Scholar
• Guy W. 1976. Clinical global impressions. In: Guy W, editor. ECDEU assessment for psychopharmacology. Rockville, MD: National Institute of Mental Health, pp. 217–222.
   Google Scholar
• Guy W. 1976. ECDEU assessment manual for psychopharmacology. Washington, DC: US Department of Health, Education, and Welfare, pp. 534–537.
   Google Scholar
• Inada T, Yagi G, Gardos G. 1996. Inter-rater reliability of the drug-induced extrapyramidal symptoms scale (DIEPSS). Abstracts of 20th Collegium Internationale Neuropsycho-Pharmacologicum, Melbourne, Australia, pp. 23–27.
   Google Scholar
• Inada T. 1996. Evaluation and diagnosis of drug-induced extrapyramidal symptoms. In: Yagi G, editor. Commentary on the DIEPSS and guide to its usage. Tokyo: Seiwa Publishers, pp. 11–60 (in Japanese).
   Google Scholar
• Inagaki A, Inada T. 2012. Dose equivalence of psychotropic drugs. Part XXIII: Dose equivalence of novel antipsychotics: pariperidone extended-release. Jpn J Clin Psychopharmacol 15:397–404 (in Japanese).
   Google Scholar
• Kaneda Y, Sumiyoshi T, Keefe R, Ishimoto Y, Numata S, Ohmori T. 2007. Brief assessment of cognition in schizophrenia: validation of the Japanese version. Psychiatry Clin Neurosci 61:602–609.
   PubMed Web of Science ®Google Scholar
• Kaneda Y, Sumiyoshi T, Nakagome K, Numara S, Tanaka T, Kamioka Y, et al. 2008. The brief assessment of cognition in schizophrenia: validation of the Japanese version (BACS-J). Seishin Igaku (Clinical Psychiatry) 50:913–917 (in Japanese).
   Google Scholar
• Kapur S, Zipursky R, Jones C, Remington G, Houle S. 2000. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 157:514–520.
   PubMed Web of Science ®Google Scholar
• Karlsson P, Dencker E, Nyberg S, Mannaert E, Boom S, Talluri K. 2006. Pharmacokinetics, dopamine D2 and Serotonin 5-HT2A receptor occupancy and safety profile of paliperidone extended-release in healthy subjects. Schizophr Res 81:85–86.
   Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13: 261–276.
   PubMed Web of Science ®Google Scholar
• Keefe RS, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, et al. 2004. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry 161:985–995.
   PubMed Web of Science ®Google Scholar
• Kern RS, Green MF, Cornblatt BA, Owen JR, McQuade RD, Carson WH, et al. 2006. The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology (Berl) 187:312–320.
   PubMed Web of Science ®Google Scholar
• Kim SW, Chung YC, Lee YH, Lee JH, Kim SY, Bae KY, et al. 2012. Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: randomized, open-label, controlled trial. Int Clin Psychopharmacol 27:267–274.
   PubMed Web of Science ®Google Scholar
• McEvoy JP. 1987. A double-blind crossover comparison of antiparkinson drug therapy: Amantazine versus anticholinergics in 90 normal volunteers, with an empasis on differential effects on memory function. J Clin Psychiatry 48:20–23.
   Google Scholar
• Mishara AL, Goldberg TE. 2004. A meta-analysis and critical review of effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiatry 55: 1013–1022.
   PubMed Web of Science ®Google Scholar
• Mori K, Nagano M, Yamashita H, Morinobu S, Yamawaki S. 2004. Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia. Progr Neuropsychopharmacol Biol Psychiatry 28:659–665.
   Google Scholar
• Owen RT. 2007. Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic. Drugs Today (Barc) 43:249–258.
   PubMed Web of Science ®Google Scholar
• Purdon SE, Jones BDW, Stip E, Labelle A, Addington D, David SR, et al. 2000. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch Gen Psychiatry 57:249–258.
   PubMed Web of Science ®Google Scholar
• Riedel M, Muller N, Spellmann I, Engel RR, Musil R, Valdevit R, et al. 2007. Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an active episode of schizophrenia. Eur Arch Psychiatry Clin Neurosci 257:402–412.
   PubMed Web of Science ®Google Scholar
• Schreiner A, Millet B, Rocca P, Franco M, Hoeben D, Lahaye M, et al. 2009. A flexible-dose study of paliperidone ER in non-acute patients with schizophrenia previously unsuccessfully treated with oral risperidone. Poster presented at the World Congress of Biological Psychiatry, June 28–July 2, Paris, France.
   Google Scholar
• Spohn HE, Strauss ME. 1989. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J Abnorm Psychol 98:367–380.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Gen K, Inoue Y. 2011. An unblinded comparison of clinical and cognitive effects of switching from first-generation antipsychotics to aripiprazole, perospirone or olanzapine in patients with chronic schizophrenia. Progr Neuropsychopharmacol Biol Psychiatry 35:161–168.
   Google Scholar
• Tzimos A, Samokhvalov V, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M. 2008. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension. Am J Geriatr Psychiatry 16:31–43.
   PubMed Web of Science ®Google Scholar
• Vermeir M, Naessens I, Remmerie B, Mannens G, Hendrickx J, Sterkens P, et al. 2008. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab Dispos 36:769–779.
   PubMed Web of Science ®Google Scholar
• Yasui-Furukori N, Hidestrand M, Spina E, Facciolá G, Scordo MG, Tybring G. 2001. Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos 29:1263–1268.
   PubMed Web of Science ®Google Scholar
• Yoon KS, Park TW, Yang JC, Kim MG, Oh KY, Park MS, Chung YC. 2012. Different safety profiles of risperidone and paliperidone extended-release: a double-blind, placebo-controlled trial with healty volunteers. Hum Psychopharmacol 27:305–314.
   PubMed Web of Science ®Google Scholar